Peripheral Blood Stem Cell Mobilization and Engraftment after Autologous Stem Cell Transplantation with Biosimilar rhG-CSF

摘要: Biosimilar versions of filgrastim [recombinant human granulocyte colony-stimulating factor (rhG-CSF)] are now widely available. To date, biosimilar rhG-CSF has demonstrated a comparable quality, safety and efficacy profile to the originator product (filgrastim [Neupogen®], Amgen Inc., CA, USA) in prevention management neutropenia. rhG-CSFs have also been used induce peripheral blood stem cell (PBSC) mobilization patients undergoing autologous transplantation (AHSCT). The authors examined effectiveness (Zarzio®, Sandoz Biopharmaceuticals, Holzkirchen, Germany) two retrospective studies across medical centers Hungary. In Study 1, 70 with hematological malignancies scheduled undergo AHSCT received chemotherapy followed by (2 × 5 μg) for facilitating neutrophil, leukocyte, platelet engraftment. study 2, 40 additional lymphoid planned PBSC mobilization. treatment was assessed average yield cluster differentiation (CD) 34+ cells number leukaphereses required. 1 (patients AHSCT), median age 56 years most were male (60%). conditioning regimens mainly high-dose melphalan (n = 41) carmustine (BiCNU®, Bristol-Myers Squibb, NJ, USA), etoposide, cytarabine BEAM (n = 21). Median times absolute neutrophil leukocyte engraftment 9 (range 8–11 days) 10 (8–12) days, respectively. time 10.5 days (7–19 days). patients’ 54 years majority (57.5%) female. interval between day mobilizing first leukapheresis 12 (9–27) days. grafts, CD34+ harvested 5.2 × 106/kg (2.22–57.07 × 106/kg). per 2.47 × 106/kg. total, 58 performed successfully patients. line previous rhG-CSF, findings this indicate that following is effective generally well tolerated setting. addition, terms kinetics cells. conclusion, use safe after AHSCT.